COVID-19 Vaccines Found to Drastically Reduce Risk of Heart Attacks and Strokes

The paradigm of COVID-19 as a purely respiratory illness has been steadily eroding, but a massive new data release has fundamentally reframed the virus's long-term stakes.[1][6]

According to a landmark cohort study published in JAMA Internal Medicine, the 2024–2025 COVID-19 vaccine formulations provided a striking secondary benefit: a nearly 24% reduction in all-cause major cardiac events among vaccinated individuals.[1][3]

The findings, which surprised even the researchers involved, suggest that the cardiovascular burden of COVID-19 in the general population may be substantially larger than official statistics reflect.[1]

The primary research, led by Dr. Ziyad Al-Aly at the Veterans Affairs St. Louis Health Care System, tracked more than one million U.S. veterans who received flu vaccinations in 2024.[2][3]

Roughly one-third of this cohort also opted for the updated COVID-19 vaccine, creating a massive natural experiment to observe cardiovascular outcomes over the subsequent eight months.[3]

The direct protection against known COVID-19 complications was substantial. Vaccine effectiveness reached 37.7% for preventing COVID-associated Major Adverse Cardiovascular Events (MACE)—a composite metric that includes heart attacks, strokes, and heart failure hospitalizations.[2][3]

When researchers broke down the specific endpoints, the protective effect became even more pronounced. The vaccine was 57.9% effective at preventing COVID-associated cardiovascular death and 41.9% effective against heart failure hospitalizations.[2][3]

However, the finding that turned heads in the medical community was the vaccine's impact on all-cause cardiac events—those not explicitly linked to a documented COVID-19 diagnosis in the patient's medical record.[1][3]

Vaccinated veterans showed a nearly 24% lower risk of these all-cause events. Dr. Al-Aly hypothesizes that millions of cardiac events currently tallied as unexplained or idiopathic likely have an invisible driver: unrecognized SARS-CoV-2 infection.[1][6]

Many individuals who experience mild or asymptomatic infections never test for the virus, yet they may arrive at an emergency room weeks later with a myocardial infarction or stroke.[1]

Because the precipitating viral infection was never documented, these severe cardiovascular events are rarely recorded as COVID-related, masking the true systemic toll of the pathogen.[1][6]

The data also revealed a stark age gradient in the cardiovascular benefits. In a subgroup analysis, the reduction in COVID-associated MACE was most statistically significant in adults older than 75 years.[2][3]

For this older demographic, vaccine effectiveness against cardiovascular complications jumped to 50.7%, translating to 5.48 fewer major cardiac events per 10,000 people compared to their unvaccinated peers.[2]

Two additional studies published concurrently reinforce the broader protective value of the updated vaccines. A CDC-led analysis by Ryan Wiegand found the 2024–2025 formulations were 41% effective against critical illness requiring urgent care.[2][4]

Meanwhile, a European case-control study published in JAMA Network Open demonstrated that the vaccines maintained a 59% effectiveness rate against symptomatic disease in older adults across multiple countries.[2][5]

Together, this evidence pack addresses lingering public hesitation regarding vaccine-induced myocarditis. The data consistently show that the cardiovascular risks posed by the virus itself dwarf the rare inflammatory side effects of the mRNA vaccines.[1][6]

For practicing clinicians, the data provide a powerful new tool for patient counseling. The conversation can now shift from abstract respiratory risks to concrete, measurable protection against heart attacks and strokes.[2][6]

Ultimately, the findings urge a recalibration of public health messaging as the world navigates the endemic phase of the virus, cementing the annual COVID-19 shot as a critical pillar of cardiovascular disease prevention.[3][6]